Barré Thomas, Vorspan Florence, Fortias Maeva, Veyrier Marc, Cavagna Pauline, Azuar Julien, Nicolas Louise, Naccache François, Barreteau Hélène, Bellivier Franck, Bloch Vanessa
Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France.
Département de psychiatrie et de médecine addictologique, hôpital Fernand Widal, AP-HP, 200, rue du faubourg-Saint-Denis, 75010 Paris, France; INSERM UMRS-1144, 75006 Paris, France.
Therapie. 2018 Dec;73(6):495-500. doi: 10.1016/j.therap.2018.03.003. Epub 2018 Mar 29.
Intranasal naloxone aims at preventing opioid overdose related deaths in active drug users. In France, it has been available since July 2016 through a temporary approval which requires a hospital-based pharmacy and a nominative registration of each patient. We present the characteristics of the first patients who could receive this prescription in our hospital-based addiction center and how they used naloxone during follow-up. Results favor a larger dispensing of naloxone. Patients' as well as peers' and families' education is needed.
鼻内使用纳洛酮旨在预防活跃吸毒者中与阿片类药物过量相关的死亡。在法国，自2016年7月起，通过临时批准可获得该药，这需要医院药房以及对每位患者进行实名登记。我们介绍了在我们医院的成瘾治疗中心首批能够获得该处方的患者的特征，以及他们在随访期间如何使用纳洛酮。结果支持更广泛地分发纳洛酮。患者以及同伴和家人的教育是必要的。
